Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Lucely Cetina

ResearcherPublications, citations & collaboration network

Lucely Cetina is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 110 works, 2,908 citations, an h-index of 29 and an i10-index of 57.

110
Works
2,908
Citations
29
h-index
57
i10-index

How has Lucely Cetina's publication output changed over time?

ScholarIQpublication output · 2003–2021

Output declined50% over the shown period — from 2 works in 2003 to 1 in 2021.

2
3
1
1
1
1
1
1
20032005200620072010201320182021

What are the most-cited papers on Lucely Cetina?

ScholarIQmost cited works
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce, Lucely Cetina, José Luis Aguilar-Ponce, Óscar Arrieta, Aurora González‐Fierro, Alma Chávez‐Blanco, Erik de la Cruz-Hernandez, Maria Fernanda Vieira Cunha Camargo, Catalina Trejo‐Becerril, Enrique Pérez‐Cárdenas, Carlos Pérez‐Plasencia, Lucía Taja‐Chayeb, Talía Wegman-Ostrosky, Alma Luísa Revilla Vázquez, Alfonso Dueñas‐González
Annals of Oncology. 2007253 Citations
Epigenetics of cervical cancer. An overview and therapeutic perspectives
Alfonso Dueñas‐González, Marcela Lizano, Myrna Candelaria, Lucely Cetina, Claudia Arce, Eduardo Cervera
S132829192. 2005233 CitationsOPEN ACCESS
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
Pilar Zambrano, Blanca Segura‐Pacheco, Enrique Pérez‐Cárdenas, Lucely Cetina, Alma Luísa Revilla Vázquez, Lucía Taja‐Chayeb, Alma Chávez‐Blanco, Enrique Ángeles, Gustavo Cabrera, Karina Sandoval, Catalina Trejo‐Becerril, José Chanona-Vilchis, Alfonso Dueñas‐González
BMC Cancer. 2005150 CitationsOPEN ACCESS
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
Jaime Coronel, Lucely Cetina, Irlanda Pacheco, Catalina Trejo‐Becerril, Aurora González‐Fierro, Erick de la Cruz‐Hernandez, Enrique Pérez‐Cárdenas, Lucía Taja‐Chayeb, Daymi Arias-Bofill, Myrna Candelaria, Sílvia Vidal, Alfonso Dueñas‐González
S204953464. 2010133 Citations
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
Alma Chávez‐Blanco, Blanca Segura‐Pacheco, Enrique Pérez‐Cárdenas, Lucía Taja‐Chayeb, Lucely Cetina, Myrna Candelaria, David Cantú de León, Aurora González‐Fierro, Patricia García‐López, Pilar Zambrano, Carlos Pérez‐Plasencia, Gustavo Cabrera, Catalina Trejo‐Becerril, Enrique Ángeles, Alfonso Dueñas‐González
S132829192. 2005129 CitationsOPEN ACCESS

Related on ScholarIQ

Instituto Nacional de Cancerología
Institution
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
Paper
Epigenetics of cervical cancer. An overview and therapeutic perspectives
Paper
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
Paper
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
Paper
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
Paper
470M+ articles · free account